Financial Data and Key Metrics Changes - For the fourth quarter of 2025, the company reported operating expenses of $91.9 million, which included $90.4 million in non-cash stock-based compensation. Excluding stock-based compensation, operating expenses were $72.5 million [26] - For the year ended 2025, total operating expenses were $384.6 million, including $75.6 million in non-cash stock-based compensation, leading to adjusted operating expenses of $309 million [27] - The company ended 2025 with $368 million in cash and cash equivalents, bolstered by $60.4 million from the exercise of warrants [11][27] Business Line Data and Key Metrics Changes - The company is focused on the launch of apitegromab, the world's first muscle-targeted therapy for SMA, with preparations underway for a U.S. launch in 2026 [4][11] - The company is also advancing its anti-myostatin pipeline, including apitegromab and SRK-439, with ongoing clinical trials and promising data from phase 1 studies [10][20] Market Data and Key Metrics Changes - The global market for SMA therapies is currently valued at nearly $5 billion in annual sales, with a significant unmet need for muscle-targeted therapies [21] - The company is engaging with approximately 140 SMA treatment centers and 2,600 prescribing physicians in the U.S. to enhance disease education and awareness [22] Company Strategy and Development Direction - The company aims to deliver apitegromab to the SMA community as quickly as possible while also expanding its pipeline for other rare neuromuscular diseases [4][12] - The company is building a 50-country operating platform in Europe and enhancing its commercial capabilities to support the launch of apitegromab [12][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing engagement with the FDA and the urgency to bring apitegromab to market, reaffirming guidance for BLA resubmission and U.S. launch in 2026 [7][29] - The company remains focused on long-term shareholder value while navigating the complexities of regulatory approvals and market readiness [28][91] Other Important Information - The company secured a new debt facility for up to $550 million to support its commercial and R&D priorities, with immediate access to $100 million [11][28] - The company is preparing for a supplemental BLA submission for a second fill-finish facility later in 2026 [14][27] Q&A Session Summary Question: Is Novo now ready for re-inspection? - Management confirmed that the gating item is a successful re-inspection of the Catalent Indiana facility, which would trigger the BLA resubmission [33][34] Question: What happens if the backup facility is needed? - Management indicated that whether it is a supplemental BLA or a fallback to the backup facility, they do not expect significant delays in timelines [36][37] Question: What was the purpose of the FDA sending a field team? - Management noted that the field team's visit indicates the FDA's high priority on the remediation of the Catalent facility and the urgency to progress the apitegromab file [40][42] Question: What are the expectations for the label regarding age subgrouping? - Management anticipates a straightforward alignment with the FDA on the final label after BLA resubmission, considering the comprehensive data already presented [62] Question: What are the expectations for the launch trajectory? - Management expects robust demand for apitegromab but acknowledges potential access speed bumps due to payer reimbursement processes [69] Question: Will the MAA review be affected by the Catalent facility? - Management confirmed that progress with the FDA will positively influence the MAA review process with the EMA [81][82]

Financial Data and Key Metrics Changes - For Q4 2025, the company reported operating expenses of $91.9 million, including $90.4 million in non-cash stock-based compensation, while excluding stock-based compensation, operating expenses were $72.5 million [24] - For the full year 2025, operating expenses totaled $384.6 million, with $75.6 million in non-cash stock-based compensation, and $309 million when excluding stock-based compensation [25] - The company ended 2025 with $368 million in cash and cash equivalents, bolstered by $60.4 million from the exercise of warrants [9][25] Business Line Data and Key Metrics Changes - The company is focused on the commercial launch of apitegromab, the first muscle-targeted therapy for SMA, with preparations underway for a U.S. launch in 2026 [6][19] - The company is also advancing its anti-myostatin pipeline, including apitegromab and SRK-439, with ongoing clinical trials and promising data from phase 1 studies [8][18] Market Data and Key Metrics Changes - The global market for SMA therapies is currently valued at nearly $5 billion in annual sales, with a significant unmet need for muscle strength and motor function treatments [20] - The company is engaging with approximately 140 SMA treatment centers and 2,600 prescribing physicians in the U.S. to enhance disease education and awareness [21] Company Strategy and Development Direction - The company aims to deliver apitegromab to the SMA community as quickly as possible while also expanding its pipeline for other rare neuromuscular diseases [3][10] - The company is building a 50-country operating platform in Europe and preparing for a launch in Germany in the second half of 2026 [10][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing engagement with the FDA and the urgency to bring apitegromab to market, anticipating a successful BLA resubmission following a reinspection of the Catalent Indiana facility [5][11] - The company remains focused on its strategic priorities and is optimistic about the transformative potential of its therapies for patients with SMA and other neuromuscular diseases [10][28] Other Important Information - The company secured a new debt facility for up to $550 million to support its commercial and R&D activities, with $100 million immediately available for use [25][27] - The company is also planning to monetize a Priority Review Voucher to further strengthen its balance sheet [27] Q&A Session Summary Question: Is Novo now ready for re-inspection? - Management confirmed that the gating item is a successful re-inspection of the Catalent Indiana facility, which would trigger the BLA resubmission [31][32] Question: What would happen if the backup facility is needed? - Management indicated that whether it is a supplemental BLA or a primary filing, they do not expect significant delays in timelines [34][36] Question: What was the purpose of the FDA sending a field team? - Management noted that the field team's visit indicates the FDA's high priority on the remediation of the Catalent facility and the urgency to bring apitegromab to patients [38][40] Question: What are the expectations for the label regarding age subgrouping? - Management anticipates a straightforward alignment with the FDA on the final label after BLA resubmission, given the progress made during the original review process [60] Question: What are the expectations for time to profitability? - Management indicated that they expect a typical rare disease revenue trajectory, leading to profitability within two to three years from launch [91]

Financial Data and Key Metrics Changes - The company ended Q3 2025 with $369.6 million in cash and cash equivalents, reporting $103 million in operating expenses, which includes $18.3 million in non-cash stock-based compensation [24][25] - Excluding stock-based compensation, operating expenses were $85.3 million, reflecting ongoing investments in infrastructure to support regulatory approval and commercial readiness [25] - The company strengthened its balance sheet by adding $141.7 million during the quarter, which included net proceeds of $91.7 million from the sale of approximately 2.8 million shares and a $50 million drawdown from an existing debt facility [25][24] Business Line Data and Key Metrics Changes - The company is focused on advancing apitegromab for spinal muscular atrophy (SMA) and has initiated dosing in a phase two OPAL trial evaluating apitegromab in infants and toddlers under the age of two [16][17] - The company is also progressing SRK-439 into clinical development, with plans to initiate a phase one study in healthy volunteers before the end of the year [18] Market Data and Key Metrics Changes - The global annual revenue for current SMA treatments is trending to approximately $5 billion, indicating a growing demand for treatments in this market [20] - There are an estimated 35,000 people with SMA who have received an SMN-targeted therapy and could be eligible for treatment with apitegromab [23] Company Strategy and Development Direction - The company aims to be a global biotech powerhouse, leveraging its expertise in myostatin biology to deliver transformative therapies for neuromuscular disorders [5] - The strategy includes executing a strong commercial launch for apitegromab and advancing its pipeline, including a second indication for apitegromab and the development of SRK-439 [28][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the eventual approval of apitegromab, emphasizing the urgency to serve the SMA community and the commitment to quality and compliance in the remediation efforts at the Bloomington facility [7][8] - The company remains focused on executing its plans with financial discipline, aiming to bring apitegromab to market as rapidly as possible while managing its cash runway effectively [28][29] Other Important Information - The company has secured commercial capacity for a second fill-finish facility, expected to commence in Q1 2026, and anticipates submitting an SBLA for this facility later in 2026 [10][15] - The company is operating with a tight financial plan and has deferred investments in several areas to prioritize strategic initiatives [25] Q&A Session Summary Question: Financing opportunities and operational risks during facility transition - Management indicated that the first objective is to bridge financing until approval, with a preference for extending the loan facility before considering equity options [32] - Regarding operational risks, management assured that transitioning between facilities should be seamless, focusing on maintaining consistency in vial configuration and analytical testing [34][35] Question: Confidence in remediation efforts at the Bloomington facility - Management acknowledged the facility's history but expressed confidence in Novo Nordisk's commitment to quality and compliance, highlighting the collaborative efforts in the remediation plan [40][41] Question: BLA submission strategy and EMA review status - The plan is to submit the BLA after the reinspection of the Bloomington facility, with expectations for a decision from the EMA on the marketing authorization application by mid-next year [16][49] Question: Timelines for reinspection and potential pivot to second fill-finish facility - Management stated that a successful reinspection is the goal, and if issues arise, the second fill-finish facility could be pivoted to serve as the primary submission strategy [56][57] Question: Disclosure plans regarding inspection outcomes - Management committed to maintaining open communication regarding important developments, including the outcomes of inspections and any material information related to the facility [74][75]